The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: Results from the US VICTORY consortium

American Journal of Gastroenterology

Volumn 111, Issue 8, 2016, Pages 1147-1155

  Dulai, Parambir S ^a   Singh, Siddharth ^a   Jiang, Xiaoqian ^a   Peerani, Farhad ^b   Narula, Neeraj ^b   Chaudrey, Khadija ^c   Whitehead, Diana ^d   Hudesman, David ^e   Lukin, Dana ^f   Swaminath, Arun ^g   Shmidt, Eugenia ^b   Wang, Shuang ^a   Boland, Brigid S ^a   Chang, John T ^a   Kane, Sunanda ^c   Siegel, Corey A ^d   Loftus, Edward V ^c   Sandborn, William J ^a   Sands, Bruce E ^b   Colombel, Jean Frederic ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g Division of Gastroenterology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ACUTE ABDOMEN; ADULT; ANASTOMOSIS LEAKAGE; ANUS DISEASE; ANUS FISTULA; ARTHRALGIA; ARTICLE; BLINDNESS; COHORT ANALYSIS; COLON MUCOSA; COLON RESECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HOSPITALIZATION; HUMAN; ILEOSTOMY; INTESTINE FISTULA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCTOCOLECTOMY; QUANTITATIVE ANALYSIS; REMISSION; RETROSPECTIVE STUDY; SMALL INTESTINE PERFORATION; SMOKING; WOUND HEALING; ANTAGONISTS AND INHIBITORS; ANUS DISEASES; CHEMICALLY INDUCED; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; OPTIC NEURITIS; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANUS DISEASES; COHORT STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; OPTIC NEURITIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84982921518     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.236     Document Type: Article

References (34)

1. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease-Algorithm for practical management. Aliment Pharmacol Ther 2016; 43: 30-51.
2. Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with Inflammatory bowel disease. Gastroenterol Clin North Am 2014; 43: 525-41.
3. Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-Tumor necrosis factor therapy for pediatric Inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014; 12: 1443-51.
4. Dulai PS, Siegel CA, Colombel JF, et al. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014; 63: 1843-53.
5. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
6. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-Analysis. Gastroenterology 2015; 148: 344-54.e5.
7. Singh S, Garg SK, Pardi DS, et al. Comparative effi cacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-Analysis. Mayo Clin Proc 2014; 89: 1621-35.
8. Dulai PS, Singh S, Casteele NV, et al. How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active Inflammatory bowel disease. Inflamm Bowel Dis 2016; 22: 998-1009.
9. Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the Inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002-7.
10. Dulai PS, Levesque BG, Feagan BG, et al. Assessment of mucosal healing in Inflammatory bowel disease: review. Gastrointest Endosc 2015; 82: 246-55.
11. Boland BS, Dulai PS, Chang M, et al. P seudomonas meningiti s during vedolizumab therapy for Crohn's disease. Am J Gastroenterol 2015; 110: 1631-2.
12. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016 [e-pub ahead of print].
13. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classifi cation of Inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
15. Vuitton L, Marteau P, Sandborn WJ, et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 2015 [e-pub ahead of print].
16. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-157.e2.
17. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-Treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-21.
18. Shelton E, Allegretti JR, Stevens B, et al. Effi cacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis 2015; 21: 2879-85.
19. Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab effectiveness and safety over the fi rst year of use in an IBD clinical practice. J Crohns Colitis 2015; 10: 402-9.
20. Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for Inflammatory bowel disease in clinical practice-A nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-102.
21. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. effectiveness and safety of vedolizumab induction therapy for patients with Inflammatory bowel disease. Clin Gastroenterol Hepatol 2016 [e-pub ahead of print].
22. Sands BE, Feagan BG, Rutgeerts P, et al. effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627.e3.
23. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111.e2.
24. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 423-31.e1.
25. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
26. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95.
27. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with metaanalysis: the effi cacy of a second anti-TNF in patients with Inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613-23.
28. Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 2016; 43: 262-71.
29. To N, Gracie DJ, Ford AC. Systematic review with meta-Analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther 2016; 43: 549-61.
30. Bergeron V, Grondin V, Rajca S, et al. Current smoking diff erentially aff ects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis 2012; 18: 1101-11.
31. Hauser IA, Johnson DR, Madri JA. Diff erential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion. J Immunol 1993; 151: 5172-85.
32. Biancheri P, Di Sabatino A, Rovedatti L, et al. effect of tumor necrosis factor-Alpha blockade on mucosal addressin cell-Adhesion molecule-1 in Crohn's disease. Inflamm Bowel Dis 2013; 19: 259-64.
33. Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for Inflammatory bowel diseases. Gastroenterology 2014; 147: 981-9.
34. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in Inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-76.